Patients who are receiving any other investigational agents or have received other investigational agents within  weeks or  half-lives of the compound or active metabolites, whichever is longer before the first dose of the study treatment
The participant has received prior treatment with a small molecule kinase inhibitor or a hormonal therapy (including investigational kinase inhibitors or hormones) within  weeks or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment; note: participants with prostate cancer currently receiving luteinizing hormone-releasing hormone (LHRH) or gonadotropin-releasing hormone (GnRH) agonists may be maintained on these agents
Patients who have received targeted or investigational agents within  weeks or within  half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapies
The subject has received prior treatment with a small molecule kinase inhibitor or a hormonal therapy (including investigational kinase inhibitors or hormones) within  days or  half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment -OR- the subject has ever taken Cabozantinib; Note: subjects with prostate cancer currently receiving luteinizing hormone releasing hormone (LHRH) or gonadotropin releasing hormone (GnRH) agonist may be maintained on these agents
Patients who are receiving any other investigational agents concurrently or have received investigational agents within  days or  half-lives of the compound or active metabolites, whichever is longer before the first dose of the study treatment
Patients who have received targeted agents within  weeks or within  half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapies
Patients who are receiving any other investigational agents concurrently or have received investigational agents within  weeks or  half-lives of the compound or active metabolites, whichever is longer before the first dose of the study treatment
Received targeted agents within  weeks or within  half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapies
The subject has received prior treatment with a small molecule kinase inhibitor or a hormonal therapy (including investigational kinase inhibitors or hormones) within  days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment
The subject has received prior treatment with a small molecule kinase inhibitor or a hormonal therapy (including investigational kinase inhibitors or hormones) within  days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment
Patients who have received investigational agents within  weeks or within  half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapies
The subject has received small-molecular kinase inhibitors or any other type of investigational agent within  weeks before the first dose of study treatment or  half-lives of the compound or active metabolite, whichever is shorter
Prior treatment with a small molecule kinase inhibitor or a hormonal therapy (including investigational kinase inhibitors or hormones) within  days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment
The subject has received prior treatment with a small molecule kinase inhibitor or a hormonal therapy (including investigational kinase inhibitors or hormones) within  days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment
Patients who have received targeted or investigational agents prior to registration within  weeks or within  half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapies
Anti-myeloma therapy, including radiotherapy, within  weeks or within  half-lives of the agent and active metabolites (whichever is longer) prior to day  and who have not recovered from side effects (to =< grade ) of those therapies
Patients who have received targeted agents within  weeks or within  half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapies
The subject has received prior treatment with a small molecule kinase inhibitor or a hormonal therapy (including investigational kinase inhibitors or hormones) within  days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment with the exception of patients receiving prior abiraterone or ketoconazole; for patients receiving prior abiraterone or ketoconazole, they must discontinue the medication within  half-lives of the compound before the first dose of study treatment in order to participate in this study; Note: subjects with prostate cancer currently receiving luteinizing-hormone-releasing hormone (LHRH) or gonadotropin-releasing hormone (GnRH) agonists must be maintained on these agents
The participant has received prior treatment with a small molecule kinase inhibitor or a hormonal therapy (including investigational kinase inhibitors or hormones) within  days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment
Patients who have received targeted agents within  weeks or within  half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapies
Patients who have received targeted agents within  weeks or within  half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapies
Prior treatment with a small molecule kinase inhibitor or a hormonal therapy (including investigational kinase inhibitors or hormones) within  days or five half-lives of the compound or active metabolites, whichever is longer, or before the first dose of study treatment
The subject has received prior treatment with a small molecule kinase inhibitor within  days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment
The subject has received prior treatment with hormonal therapy within  days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment; subjects receiving gonadotropin-releasing hormone (GnRH) agonists and antagonists are allowed to participate
Patients who have received targeted agents within  weeks or within  half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapies
Subject has received small-molecular kinase inhibitors or any other type of investigational agent within  weeks before the first dose of study treatment or  half-lives of the compound or active metabolite, whichever is shorter
The subject has received prior treatment with a small molecule kinase inhibitor or a hormonal therapy (including investigational kinase inhibitors or hormones) within  days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment
Patients who have received targeted agents within  weeks or within  half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapies
